Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31547213 | 1.00 | HSP90AA1 (0.49) | HSP90AA1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL3731571 | 1.00 | HSP90AA1 (0.49) | HSP90AA1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL6516804 | 0.98 | KMT2A (0.48) | HSP90AA1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL6516806 | 0.98 | KMT2A (0.48) | HSP90AA1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL28546334 | 0.88 | MAOB (0.50) | KMT2AMEN1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL5572239 | 0.88 | MAOB (0.50) | KMT2AMEN1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL31547242 | 0.81 | RAB9A (0.43) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL16825154 | 0.79 | NFE2L2 (0.57) | MAPTSMN1; SMN2NPC1RAB9AMAOB | |
| SCHEMBL13041010 | 0.78 | SIGMAR1 (0.58) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL22230801 | 0.78 | GPR183 (0.43) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935292-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-04-10 | — | — | EP | disclosed |
| US-20150333280-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| US-20150333280-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-11-19 | — | — | US | disclosed |
| WO-2014094961-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-06-26 | — | — | WO | disclosed |
| WO-2012150829-A2 | NOBLE TRIAZOLOPYRIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 제일약품주식회사 (KR) | 2012-11-08 | — | — | WO | disclosed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| WO-2005077885-A1 | RUTHENIUM-CATALYZED HYDROAMINATION OF OLEFINS | YALE UNIVERSITY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150333280-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | HSP90AA1 4261/4885KMT2A 2922/4885MEN1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.